Katarzyna Joanna Jerzak

University of Toronto
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Background: Neoadjuvant systemic therapy (NST) is often used to treat locally advanced breast cancer (BC) or patients with early-stage BC at high risk for micrometastatic spread. Pathological complete response (pCR) to NST in BC is associated with excellent prognostic outcomes; however, rates vary significantly. Tumor-infiltrating lymphocytes (TILs) are associated with NST response, suggesting potential as predictive biomarkers. Objective: To develop a computer vision approach to quantify spatial TIL parameters and a multiparametric machine learning (ML) model for predicting NST response. Design: Retrospective, single institution study of 411 BC patients, combining clinical and graph-level pre-treatment histopathology data to predict response to NST using ML. Methods: Pre-treatment core needle biopsies were prepared, stained with hematoxylin and eosin, and digitized into whole slide images. Convolutional neural networks were applied to segment and classify regions of invasive carcinoma and TILs. Spatial features were extracted based on the coordinates of the TILs within invasive regions, including metrics from Delaunay triangulation, Voronoi diagram analysis, and minimum spanning trees, as well as features capturing cell density and nuclear count. Clinicopathological features were incorporated to support multiparametric modeling. Multiple ML classification models were trained to predict pCR. Logistic regression, K-nearest neighbor, support vector, random forest, Gaussian Naïve Bayes, and extreme gradient boosting models were tested, and model performances were reported. Results: ML models using clinical and graph-based features achieved high predictive accuracy. The best performing graph feature model reached an area under the receiver operating characteristic curve (AUC) of 0.924. Ensemble models integrating clinical and graph features showed the highest performance, with an AUC of 0.955. Notably, for triple-negative BC, significant differences in predictive performance were demonstrated between clinical and graph feature models ( p = 0.026) and between clinical and ensemble models ( p = 0.006). Conclusion: Multiparametric modeling utilizing clinicopathological and graph features obtained from TILs is associated with pCR in BC patients treated with NST.

Year:

2026

PURPOSE Human epidermal growth factor receptor 2 (HER2)-low is a newly defined subgroup of HER2-negative breast cancer. It is unknown whether HER2-low status is associated with brain metastases (BrM) development. We aimed to determine the association between HER2-low status and the time to developing BrM. METHODS HER2 status was determined in a cohort of 689 women with metastatic breast cancer (MBC) who underwent treatment for BrM at Sunnybrook Odette Cancer Centre from 2008 to 2018. In patients with primary breast cancer (PBC) HER2 subclassification available (subgroup 1), we investigated time from PBC diagnosis to BrM diagnosis (PBC-time to brain metastases [TTBM]). In patients with HER2 subclassification available in any tissue (subgroup 2), we investigated time from MBC diagnosis to BrM diagnosis (MBC-TTBM). RESULTS In subgroup 1 (n = 175), patients with HER2-low disease (n = 42) had a shorter PBC-TTBM compared with those with HER2-zero disease (n = 77; hazard ratio, 2.4; P = .0003). When stratified by hormone receptor (HR) status, this observation held true in the HR+/HER2– population, but not in the triple-negative breast cancer (TNBC) population. In subgroup 2 (n = 279), patients with HER2-low disease (n = 53) had a shorter MBC-TTBM compared to those with HER2-zero disease (n = 44) in the HR+/HER2– population (hazard ratio, 1.55; P = .036); however, this did not hold true in the TNBC population. Likelihood ratio test revealed significant interaction between HER2 and HR status in subgroup 2 ( P = .016), but not subgroup 1 ( P = .21). CONCLUSION Our findings suggest that among patients with HR+ breast cancer, HER2-low status was associated with shorter TTBM compared with HER2-zero status. In a subset of patients for whom HER2 status of the PBC was available, HER2-low status was associated with shorter PBC-TTBM, irrespective of HR status. This study suggests a previously unrecognized association between HER2-low status and timing of BrM development.

Year:

2025

Purpose: Patients with postpartum breast cancer diagnosed after cessation of breastfeeding (postweaning, PP-BC PW ) have a particularly poor prognosis compared with patients diagnosed during lactation (PP-BC DL ), or to pregnant (Pr-BC) and nulliparous (NP-BC) patients, regardless of standard prognostic characteristics. Animal studies point to a role of the involution process in stimulation of tumor growth in the mammary gland. However, in women, the molecular mechanisms that underlie this poor prognosis of patients with PP-BC PW remain vastly underexplored, due to of lack of adequate patient numbers and outcome data. Experimental Design: We explored whether distinct prognostic features, common to all breast cancer molecular subtypes, exist in postpartum tumor tissue. Using detailed breastfeeding data, we delineated the postweaning period in PP-BC as a surrogate for mammary gland involution and performed whole transcriptome sequencing, immunohistochemical, and (multiplex) immunofluorescent analyses on tumor tissue of patients with PP-BC PW , PP-BC DL , Pr-BC, and NP-BC. Results: We found that patients with PP-BC PW having a low expression level of an immunoglobulin gene signature, but high infiltration of plasma B cells, have an increased risk for metastasis and death. Although PP-BC PW tumor tissue was also characterized by an increase in CD8 + cytotoxic T cells and reduced distance among these cell types, these parameters were not associated with differential clinical outcomes among groups. Conclusions: These data point to the importance of plasma B cells in the postweaning mammary tumor microenvironment regarding the poor prognosis of PP-BC PW patients. Future prospective and in-depth research needs to further explore the role of B-cell immunobiology in this specific group of young patients with breast cancer.

Year:

2025

PURPOSE Trastuzumab deruxtecan is a new treatment option for patients with advanced human epidermal growth factor receptor 2 (HER2)–low breast cancer (BC). Although HER2-low status has been characterized in early and advanced BC, it has yet to be fully characterized in brain metastases (BrM). METHODS Patients who underwent surgery for BC BrM at Sunnybrook Health Sciences Centre and for whom HER2 status was available on resected BrM were studied. Estrogen receptor, progesterone receptor, and HER2 status were assessed on the basis of ASCO/College of American Pathologists (CAP) guidelines. HER2-zero was defined as immunohistochemistry (IHC) 0; HER2-low was defined as IHC 1+ or IHC 2+ with fluorescence in situ hybridization (FISH)–negative status. HER2-positive (HER2+) was defined as IHC 3+ or IHC 2+ with positive FISH. Clinicopathologic features were recorded. We also assessed the prognostic association between extent of HER2 expression and (1) brain-specific progression-free survival (bsPFS), as well as (2) overall survival (OS). RESULTS In this retrospective cohort of 102 patients with resected BC BrM, 53% (n = 54) were HER2+, 29.4% (n = 30) were HER2-low, and 17.6% (n = 18) had HER2-zero status. Among BrM that were triple-negative on the basis of ASCO/CAP guidelines, 63.6% (n = 14/22) were reclassified as being HER2-low. Sixty percent (n = 15/25) of BrM that were hormone receptor–positive/HER2-negative (HR+/HER2–) were reclassified as being HER2-low. In total, 51 patients had matched primary breast and BrM tissue available; results of HER2 status when categorized as HER2-zero, HER2-low, and HER2+ were concordant in 82.3% (n = 42/51) of cases (Cohen's kappa, 0.58; P = .07). There was no significant association between HER2-zero, HER2-low, and HER2+ status in BrM and either bsPFS or OS. CONCLUSION Among patients with surgically resected BrM, a high proportion of those with metastatic triple-negative BC and HR+/HER2– disease have HER2-low BrM with potential to benefit from HER2-targeted therapy.

Year:

2024

Purpose: Postpartum breast cancer patients diagnosed after cessation of breastfeeding (post-weaning, PP-BC PW ), have a particularly poor prognosis compared to patients diagnosed during lactation (PP-BC DL ), or to pregnant (Pr-BC) and nulliparous (NP-BC) patients, irrespective of standard prognostic characteristics. Animal studies point to a role of the involution process in stimulation of tumor growth in the mammary gland. However, in women, the molecular mechanisms that underlie this poor prognosis of PP-BC PW patients remain vastly underexplored, due to of lack of adequate patient numbers and outcome data. Experimental Design: We explored whether distinct prognostic features, common to all breast cancer molecular subtypes, exist in postpartum tumor tissue. Using detailed breastfeeding data, we delineated the post-weaning period in PP-BC as a surrogate for mammary gland involution and performed whole transcriptome sequencing, immunohistochemical and (multiplex) immunofluorescent analyses on tumor tissue of PP-BC PW , PP-BC DL , Pr-BC and NP-BC patients. Results: We found that PP-BC PW patients having a low expression level of an immunoglobulin gene signature, but high infiltration of plasma B-cells, have an increased risk for metastasis and death. Although PP-BC PW tumor tissue was also characterized by an increase in CD8+ cytotoxic T-cells and reduced distance among these cell types, these parameters were not associated with differential clinical outcomes among groups. Conclusion: These data point to the importance of plasma B-cells in the post-weaning mammary tumor microenvironment regarding the poor prognosis of PP-BC PW patients. Future prospective and in-depth research needs to further explore the role of B-cell immunobiology in this specific group of young breast cancer patients.

Year:

2024

PURPOSE Ductal carcinoma in situ (DCIS) is routinely treated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS). The inability to accurately estimate an individual's risk of local recurrence (LR) and invasive LR using clinicopathologic factors (CPF) contributes to the overtreatment of DCIS. We examined the impact of the 12-gene DCIS Score (DS) and the 21-gene Recurrence Score (RS) on the accuracy of predicting LR and invasive LR. METHODS A population-based cohort diagnosed with pure DCIS treated with BCS ± RT from 1994 to 2003 was used. All patients had expert pathology review and assessment of the DS and RS. Predictive models (CPF alone, DS + CPF, and RS + CPF) were developed using multivariable Cox regression analyses to predict 10-year LR and invasive LR risks. Models were evaluated on the basis of c-statistic, –2log likelihood estimate (–2LLE), and Akaike information criterion. Calibration was performed using bootstrap resamples, with replacement. RESULTS The cohort includes 1,226 women treated with BCS; 712 received RT. 194 women (15.8%) experienced ipsilateral LR as a first event; 112 were invasive. Models including the DS or RS performed better in predicting the 10-year risk of LR compared with models on the basis of CPF alone with excellent calibration. The two molecular-based models also performed better in predicting invasive LR compared with the CPF model but the model incorporating the RS did not perform better in the prediction of invasive LR compared with the DS-based model. CONCLUSION Models incorporating the DS or RS more accurately predicted the 10-year risk of LR and invasive LR after BCS compared with models on the basis of CPF alone. Inclusion of the RS, compared with DS, did not improve the prediction of the 10-year risk of invasive LR.

Year:

2024

Collaborators (9)

Lodewyk Wessels

Professor

Delft University of Technology

NETHERLANDS
View details

Patrick Neven

University Hospitals Leuven

BELGIUM
View details

Kristel Van Calsteren

KU Leuven

BELGIUM
View details

Diether Lambrechts

Science Director

KU Leuven

BELGIUM
View details

Eileen Rakovitch

University of Toronto

CANADA
View details

Frédéric Amant

Antoni van Leeuwenhoek Nederlands Kanker Instituut

NETHERLANDS
View details

Ellen Warner

University of Toronto

CANADA
View details

Charlotte Maggen

Vrije Universiteit Brussel

BELGIUM
View details

Fedro Peccatori

Director, Fertility nd Procreation in Oncology Unit

European Institute of Oncology

ITALY
View details